Description

Palbocib 125 mg contains Palbociclib, a selective cyclin-dependent kinase (CDK) 4 and 6 inhibitor. It is commonly prescribed in combination with endocrine therapy such as aromatase inhibitors or fulvestrant for HR-positive, HER2-negative breast cancer.

🔬 Mechanism of Action

Palbociclib blocks CDK4 and CDK6 enzymes, which regulate the cell cycle transition from the G1 phase to the S phase. By inhibiting this pathway, it prevents cancer cells from multiplying, thereby slowing tumor growth and enhancing the effect of hormonal therapy.

💊 Indications

Palbocib 125 mg is indicated for:

• HR-positive, HER2-negative advanced or metastatic breast cancer
• Use in combination with an aromatase inhibitor as initial endocrine-based therapy
• Use with fulvestrant in patients with disease progression
• May be combined with ovarian suppression in premenopausal women (as prescribed)

📌 Key Features of Palbocib 125 mg

• Strength: 125 mg
• Dosage Form: Oral capsule
• Therapeutic Class: CDK4/6 Inhibitor
• Typical Regimen: 125 mg once daily for 21 consecutive days followed by 7 days off (28-day cycle), as directed by an oncologist
• Monitoring: Regular complete blood count (CBC) required due to risk of neutropenia

⚕️ Benefits of Palbociclib

• Targeted therapy for HR-positive breast cancer
• Improves progression-free survival
• Oral administration for patient convenience
• Enhances effectiveness of hormonal therapy

⚠️ Precautions

• Risk of neutropenia and infections
• Fatigue, nausea, and hair thinning may occur
• Dose adjustments may be necessary based on blood counts
• Avoid use during pregnancy
• Use strictly under oncologist supervision

Palbocib 125 mg (Palbociclib Capsules) provides an advanced, targeted treatment option for HR-positive, HER2-negative breast cancer, supporting improved disease control and better patient outcomes when used as part of combination endocrine therapy.